#FabryDisease is severe and causes considerable burden in female patients, according to a study that appeared in the Journal of Medical Genetics. The study also showed that #Migalastat is efficient in the long term in these patients.
Learn more: https://bit.ly/3KB4ahQ
#RareDisease #MedSky #RareSky
Learn more: https://bit.ly/3KB4ahQ
#RareDisease #MedSky #RareSky
Migalastat Efficient in Female Patients With Fabry Disease
Fabry disease is severe and causes considerable burden in female patients and migalastat is efficient in the long term in these patients.
bit.ly
October 6, 2025 at 5:06 PM
#FabryDisease is severe and causes considerable burden in female patients, according to a study that appeared in the Journal of Medical Genetics. The study also showed that #Migalastat is efficient in the long term in these patients.
Learn more: https://bit.ly/3KB4ahQ
#RareDisease #MedSky #RareSky
Learn more: https://bit.ly/3KB4ahQ
#RareDisease #MedSky #RareSky
Police also charged the woman with "possession of dangerous drugs," and possession of a schedule II controlled substance.
The Georgia legislature has classified misoprostol as a dangerous drug, as well as mifepristone:
law.justia.com/codes/georgi...
The Georgia legislature has classified misoprostol as a dangerous drug, as well as mifepristone:
law.justia.com/codes/georgi...
March 13, 2026 at 6:17 PM
Police also charged the woman with "possession of dangerous drugs," and possession of a schedule II controlled substance.
The Georgia legislature has classified misoprostol as a dangerous drug, as well as mifepristone:
law.justia.com/codes/georgi...
The Georgia legislature has classified misoprostol as a dangerous drug, as well as mifepristone:
law.justia.com/codes/georgi...
18/n🧬 Fabry Treatment Options 🚀
🔹 ERT 💉 – Agalsidase alfa/beta
🔹 Chaperone Therapy 🏥 – Migalastat (for amenable GLA mutations)
🔹 SRT 🛑 – In trials!
🔹 Gene Therapy 🧬 – Future potential!
#ECNeph @myadla.bsky.social @theisn.org @arunkumarnephro.bsky.social
🔹 ERT 💉 – Agalsidase alfa/beta
🔹 Chaperone Therapy 🏥 – Migalastat (for amenable GLA mutations)
🔹 SRT 🛑 – In trials!
🔹 Gene Therapy 🧬 – Future potential!
#ECNeph @myadla.bsky.social @theisn.org @arunkumarnephro.bsky.social
March 7, 2025 at 4:56 PM
18/n🧬 Fabry Treatment Options 🚀
🔹 ERT 💉 – Agalsidase alfa/beta
🔹 Chaperone Therapy 🏥 – Migalastat (for amenable GLA mutations)
🔹 SRT 🛑 – In trials!
🔹 Gene Therapy 🧬 – Future potential!
#ECNeph @myadla.bsky.social @theisn.org @arunkumarnephro.bsky.social
🔹 ERT 💉 – Agalsidase alfa/beta
🔹 Chaperone Therapy 🏥 – Migalastat (for amenable GLA mutations)
🔹 SRT 🛑 – In trials!
🔹 Gene Therapy 🧬 – Future potential!
#ECNeph @myadla.bsky.social @theisn.org @arunkumarnephro.bsky.social
NEWS: ( NASDAQ: #FOLD ) Amicus Therapeutics Announces Settlement of Galafold (migalastat) Patent Litigation with Teva
#StockMarket #News
#StockMarket #News
October 17, 2024 at 2:35 PM
"Reimbursement for oral Fabry disease drug Galafold expanded to 1st-line treatment"
#Caregiving #Healthcare #ElderCare #MedSky
#Caregiving #Healthcare #ElderCare #MedSky
Reimbursement for oral Fabry disease drug Galafold expanded to 1st-line treatment
Hanok's Fabry disease treatment, Galafold (migalastat), will have its insurance coverage criteria expanded to include first-line therapy starting this month.Previously, Galafold was eligible for insurance coverage for patients aged 16 years or older who had received enzyme replacement therapy (ERT)
www.koreabiomed.com
August 1, 2025 at 8:00 AM
"Reimbursement for oral Fabry disease drug Galafold expanded to 1st-line treatment"
#Caregiving #Healthcare #ElderCare #MedSky
#Caregiving #Healthcare #ElderCare #MedSky
"Galafold confirms effectiveness in treating teens with Fabry disease"
#Health #Healthcare #ElderCare #MedSky
#Health #Healthcare #ElderCare #MedSky
Galafold confirms effectiveness in treating teens with Fabry disease
A new study confirms that the oral treatment for Fabry disease, Galafold (migalastat), is effective in pediatric patients aged 12 to 18.Handok said Wednesday that the results of the ASPIRE study of Galafold in pediatric patients were published in May in the international journal Molecular Genetics a
www.koreabiomed.com
June 25, 2025 at 8:01 AM
"Galafold confirms effectiveness in treating teens with Fabry disease"
#Health #Healthcare #ElderCare #MedSky
#Health #Healthcare #ElderCare #MedSky
Enzyme-activating drugs are rare but impactful: riociguat allosterically stimulates sGC, dorzagliatin restores glucose-dependent glucokinase activity, and migalastat rescues misfolded α-galactosidase A in Fabry disease. These cases show how precise conformational control can enhance enzymes safely.
May 23, 2026 at 10:58 AM
Enzyme-activating drugs are rare but impactful: riociguat allosterically stimulates sGC, dorzagliatin restores glucose-dependent glucokinase activity, and migalastat rescues misfolded α-galactosidase A in Fabry disease. These cases show how precise conformational control can enhance enzymes safely.
